Systemic Erythropoietin Injection in Patients Having Optic Atrophy

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04680143

Enrollment

Registered

2020-12-22

Start date

2020-09-01

Completion date

2021-03-30

Last updated

2021-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optic Atrophy

Brief summary

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

Detailed description

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.

Interventions

DRUGSystemic erythropoietin injection

Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

The study included 10 patients diagnosed as post papilledemic optic atrophy that were attending Alexandria main university hospital. All patients underwent initially assessment of visual acuity, color vision, pupil reaction ,funduscopy and electrophysiological tests ( pattern visual evoked potential and pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control). Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Post papilledemic optic atrophy patients

Exclusion criteria

* Refuse to give an informed consent

Design outcomes

Primary

Measure	Time frame	Description
Visual acuity	3 months	VIsual acuity assessed at the follow up
Pattern visual evoked Potential .	3 months	Pattern visual evoked Potential .in both eyes to use data of the normal fellow eye as patients' internal control
Pattern electroretinogram	3 months	Pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026